Loading...
XSTO
SCIB
Market cap34mUSD
Jul 09, Last price  
32.65SEK
1D
-1.80%
1Q
8,583.51%
Jan 2017
73.86%
IPO
-32.45%
Name

SciBase Holding AB (publ)

Chart & Performance

D1W1MN
XSTO:SCIB chart
P/E
—
P/S
8.25
EPS
—
Div Yield, %
—
Shrs. gr., 5y
44.93%
Rev. gr., 5y
33.56%
Revenues
40m
+36.21%
097,0001,600,0004,151,0006,436,0006,859,0006,899,0009,276,0009,521,00011,727,00017,890,00023,245,00029,705,00040,461,000
Net income
-87m
L+42.43%
-40,964,393-79,502,000-38,755,000-41,532,000-53,086,000-42,464,000-44,215,000-39,539,000-34,989,000-41,690,000-39,899,000-55,585,000-61,125,000-87,063,000
CFO
-85m
L+47.39%
-36,437,540-34,026,000-37,077,000-46,588,000-47,850,000-44,180,000-37,482,000-37,956,000-33,861,000-39,501,000-44,466,000-51,984,000-57,383,000-84,578,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
URL
https://www.scibase.com
IPO date
Jun 02, 2015
Employees
22
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT